ALC vs IOVA
Alcon Inc vs Iovance Biotherapeutics, Inc. — AI-powered side-by-side comparison
VS
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
| Metric | ALC | IOVA |
|---|
| AI Score |
68
|
67
|
| Price |
$75.39
|
$6.49
|
| P/E Ratio |
45.39×
|
-9.27×
|
| ROE |
4.4%
|
-56.0%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
116.3%
|
| Debt / Equity |
0.24×
|
0.06×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
79.2
|
| Beta |
0.703
|
0.701
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus IOVA.
ALC leads by 1 points.
ALC scores 68/100 (Buy) versus IOVA at 67/100 (Buy).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical